Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT116 + anti-HER3 antibody conjugated to topoisomerase I inhibitor
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**BNT116 + anti-HER3 antibody conjugated to topoisomerase I inhibitor** is an experimental combination therapy currently studied in advanced non-small cell lung cancer (NSCLC)[1][2]. - **BNT116** is an mRNA-based therapy developed by BioNTech designed as a cancer vaccine to stimulate immune response against NSCLC antigens. - The **anti-HER3 antibody conjugated to a topoisomerase I inhibitor** is an antibody-drug conjugate (ADC) targeting the receptor HER3 (ERBB3) on tumor cells. This ADC delivers a cytotoxic topoisomerase I inhibitor directly to HER3-expressing cells, causing DNA damage and cell death. - The combination aims to provide synergistic antitumor activity by combining immune stimulation (BNT116) with targeted cytotoxicity (anti-HER3 ADC). - Currently evaluated in early-phase clinical trials for NSCLC[1][2]. - Both components are administered intravenously.
- Other names
- BNT116 + anti-HER3 ADC with topoisomerase I inhibitor payload
02
Targets
TOP1 (DNA Topoisomerase I)CT83 (Kita-Kyushu lung cancer antigen 1)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on BNT116 + anti-HER3 antibody conjugated to topoisomerase I inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT116 + anti-HER3 antibody conjugated to topoisomerase I inhibitor.